Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NLA-102
- Development stage
- Unknown
- Lead developer
- Nohla Therapeutics
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
**NLA-102** is an investigational universal donor stem cell therapy developed by Nohla Therapeutics using their novel stem cell technology platform. It is one of the company's two lead programs (alongside NLA-101), designed for potential use in treating hematologic malignancies or other conditions requiring hematopoietic stem cell transplantation. The therapy leverages universal donor cells to enable off-the-shelf use without the need for HLA matching, addressing key limitations in allogeneic stem cell therapies. Backed by $43.5M in investor funding specifically supporting NLA-101 and NLA-102, it represents an advancement in accessible cell-based treatments.[13]
Beyond the preview
Go deeper on NLA-102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NLA-102.